Akari Therapeutics vs PLDT

Akari Therapeutics is a biopharmaceutical company focused on developing treatments for rare and orphan autoimmune and inflammatory diseases. On the other hand, PLDT is a telecommunications company operating in the Philippines. Both companies belong to different industries, making them attractive options for investors looking to diversify their portfolio. While Akari Therapeutics offers potential growth in the healthcare sector, PLDT provides stability in the telecommunications industry. Investors should carefully consider their investment goals and risk tolerance when choosing between these two stocks.

Akari Therapeutics or PLDT?

When comparing Akari Therapeutics and PLDT, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Akari Therapeutics and PLDT.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Akari Therapeutics has a dividend yield of -%, while PLDT has a dividend yield of 6.65%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Akari Therapeutics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, PLDT reports a 5-year dividend growth of 28.05% year and a payout ratio of 77.60%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Akari Therapeutics P/E ratio at -1.19 and PLDT's P/E ratio at 12.27. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Akari Therapeutics P/B ratio is -6.49 while PLDT's P/B ratio is 2.89.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Akari Therapeutics has seen a 5-year revenue growth of 0.00%, while PLDT's is 0.28%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Akari Therapeutics's ROE at 1043.99% and PLDT's ROE at 24.42%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $2.37 for Akari Therapeutics and $26.02 for PLDT. Over the past year, Akari Therapeutics's prices ranged from $1.08 to $4.40, with a yearly change of 308.16%. PLDT's prices fluctuated between $21.34 and $30.39, with a yearly change of 42.41%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.